Recursion Pharmaceuticals Forecast, price target & analysts
Why the stock moved Beta
Recursion Pharmaceuticals Target price 2026 - Analyst rating & recommendation
Recursion Pharmaceuticals Classifications & Recommendation
Recursion Pharmaceuticals Price Target
| Target Price | $6.12 |
| Price | $3.83 |
| Potential |
59.79%
register free of charge
|
| Number of Estimates | 8 |
|
8 Analysts have issued a price target Recursion Pharmaceuticals 2027 .
The average Recursion Pharmaceuticals target price is $6.12.
This is
59.79%
register free of charge
$10.50
174.15%
register free of charge
$4.04
5.48%
register free of charge
|
|
| A rating was issued by 13 analysts: 8 Analysts recommend Recursion Pharmaceuticals to buy, 5 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Recursion Pharmaceuticals stock has an average upside potential 2027 of
59.79%
register free of charge
|
Sales and Margin forecast 2026, 2027 & 2028
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Million $ | 74.68 | 43.75 |
| 26.92% | 41.42% | |
| EBITDA Margin | -800.52% | -1,080.89% |
| 2.35% | 35.02% | |
| Net Margin | -863.36% | -1,150.77% |
| 9.56% | 33.29% |
10 Analysts have issued a sales forecast Recursion Pharmaceuticals 2026 . The average Recursion Pharmaceuticals sales estimate is
This results in the following potential growth metrics:
7 Analysts have issued an Recursion Pharmaceuticals EBITDA forecast 2026. The average Recursion Pharmaceuticals EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
10 Recursion Pharmaceuticals Analysts have issued a net profit forecast 2026. The average Recursion Pharmaceuticals net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 & 2028
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -1.44 | -0.94 |
| 14.79% | 34.72% | |
| P/E | negative | |
| EV/Sales | 34.80 |
10 Analysts have issued a Recursion Pharmaceuticals forecast for earnings per share. The average Recursion Pharmaceuticals EPS is
This results in the following potential growth metrics and future valuations:
Recursion Pharmaceuticals...
Current Recursion Pharmaceuticals Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Morgan Stanley |
Locked
➜
Locked
|
Locked | May 14 2026 |
| Needham |
Locked
➜
Locked
|
Locked | May 07 2026 |
| JP Morgan |
Locked
➜
Locked
|
Locked | Apr 30 2026 |
| B of A Securities |
Locked
➜
Locked
|
Locked | Feb 26 2026 |
| Needham |
Locked
➜
Locked
|
Locked | Feb 26 2026 |
| JP Morgan |
Locked
➜
Locked
|
Locked | Dec 17 2025 |
| Needham |
Locked
➜
Locked
|
Locked | Sep 11 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
Morgan Stanley:
Locked
➜
Locked
|
May 14 2026 |
|
Locked
Needham:
Locked
➜
Locked
|
May 07 2026 |
|
Locked
JP Morgan:
Locked
➜
Locked
|
Apr 30 2026 |
|
Locked
B of A Securities:
Locked
➜
Locked
|
Feb 26 2026 |
|
Locked
Needham:
Locked
➜
Locked
|
Feb 26 2026 |
|
Locked
JP Morgan:
Locked
➜
Locked
|
Dec 17 2025 |
|
Locked
Needham:
Locked
➜
Locked
|
Sep 11 2025 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
